SG11201903032SA - Methods and compositions related to nk cell and anti-pdl1 cancer therapies - Google Patents

Methods and compositions related to nk cell and anti-pdl1 cancer therapies

Info

Publication number
SG11201903032SA
SG11201903032SA SG11201903032SA SG11201903032SA SG11201903032SA SG 11201903032S A SG11201903032S A SG 11201903032SA SG 11201903032S A SG11201903032S A SG 11201903032SA SG 11201903032S A SG11201903032S A SG 11201903032SA SG 11201903032S A SG11201903032S A SG 11201903032SA
Authority
SG
Singapore
Prior art keywords
suite
florida
international
orlando
parkway
Prior art date
Application number
SG11201903032SA
Other languages
English (en)
Inventor
Alicja J Copik
Robert Y Igarashi
Jeremiah J Oyer
Deborah A Altomare
Original Assignee
University Of Central Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Central Florida Research Foundation Inc filed Critical University Of Central Florida Research Foundation Inc
Publication of SG11201903032SA publication Critical patent/SG11201903032SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201903032SA 2016-10-05 2017-10-05 Methods and compositions related to nk cell and anti-pdl1 cancer therapies SG11201903032SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404520P 2016-10-05 2016-10-05
PCT/US2017/055352 WO2018067825A1 (en) 2016-10-05 2017-10-05 Methods and compositions related to nk cell and anti-pdl1 cancer therapies

Publications (1)

Publication Number Publication Date
SG11201903032SA true SG11201903032SA (en) 2019-05-30

Family

ID=61831979

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903032SA SG11201903032SA (en) 2016-10-05 2017-10-05 Methods and compositions related to nk cell and anti-pdl1 cancer therapies

Country Status (11)

Country Link
US (2) US20190309070A1 (enExample)
EP (1) EP3523416B1 (enExample)
JP (2) JP7239179B2 (enExample)
KR (2) KR20240042177A (enExample)
CN (2) CN109952369B (enExample)
AU (2) AU2017340633B2 (enExample)
CA (1) CA3039532A1 (enExample)
DK (1) DK3523416T3 (enExample)
ES (1) ES3014658T3 (enExample)
SG (1) SG11201903032SA (enExample)
WO (1) WO2018067825A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
KR102373502B1 (ko) 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
WO2019226649A1 (en) * 2018-05-22 2019-11-28 Nantkwest, Inc. Optimization of nk-92 cell growth using poloxamer
CN109939127A (zh) * 2018-06-13 2019-06-28 阿思科力(苏州)生物科技有限公司 Nk细胞的应用及包括该nk细胞的药物组合物及其应用
CN113365663B (zh) 2018-08-30 2025-11-21 免疫生物公司 单链嵌合多肽和其用途
JP7474769B2 (ja) * 2018-08-30 2024-04-25 エイチシーダブリュー バイオロジックス インコーポレイテッド 一本鎖および多鎖キメラポリペプチドならびにその使用方法
KR20250160211A (ko) 2018-08-30 2025-11-11 이뮤니티바이오, 인크. 다중-사슬 키메라 폴리펩타이드 및 이의 용도
EP3880232A4 (en) * 2018-11-15 2022-08-10 Torque Therapeutics, Inc. METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
CN109652504B (zh) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 一种同时检测外泌体膜蛋白和mRNA的方法
CN110205296B (zh) * 2019-01-29 2021-08-24 上海鑫湾生物科技有限公司 具有Fc突变体的抗体与效应细胞的组合、用途和制法
US11738052B2 (en) 2019-06-21 2023-08-29 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023024168A (ja) * 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
KR20240099387A (ko) * 2021-11-09 2024-06-28 우젠 인코포레이티드 기억 nk 세포 및 항암 이중특이적 분자를 사용한 병용 암 요법
WO2023247324A1 (en) * 2022-06-24 2023-12-28 Cytovac A/S Novel combination treatment with adoptive cellular therapy
WO2024108058A2 (en) * 2022-11-18 2024-05-23 Nkmax Co., Ltd. Methods of inducing pd-l1 expression
WO2025010297A1 (en) * 2023-07-05 2025-01-09 Immunitybio, Inc. Ex vivo generation of immune effector cells from apheresis material intermediates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
KR20190134832A (ko) * 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
EP4279579A3 (en) * 2012-06-28 2024-02-21 University Of Central Florida Research Foundation Incorporated Methods and compositions for natural killer cells
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
CA2965952A1 (en) * 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
DK4141032T3 (da) * 2014-11-20 2024-08-05 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
EP3259352A4 (en) * 2015-02-19 2018-12-05 University of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
JP6826055B2 (ja) * 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法

Also Published As

Publication number Publication date
DK3523416T3 (da) 2025-03-03
KR102650803B1 (ko) 2024-03-25
EP3523416A4 (en) 2020-04-15
CN118453850A (zh) 2024-08-09
CN109952369A (zh) 2019-06-28
KR20190066035A (ko) 2019-06-12
CN109952369B (zh) 2024-03-22
AU2024202350A1 (en) 2024-05-02
EP3523416B1 (en) 2025-02-19
US20190309070A1 (en) 2019-10-10
AU2017340633A1 (en) 2019-05-23
KR20240042177A (ko) 2024-04-01
JP2019534258A (ja) 2019-11-28
ES3014658T3 (en) 2025-04-23
CA3039532A1 (en) 2018-04-12
JP2023078140A (ja) 2023-06-06
AU2017340633B2 (en) 2024-01-11
JP7239179B2 (ja) 2023-03-14
EP3523416A1 (en) 2019-08-14
WO2018067825A1 (en) 2018-04-12
US20250136698A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
SG11201903032SA (en) Methods and compositions related to nk cell and anti-pdl1 cancer therapies
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201804710TA (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201808990QA (en) Compositions for topical application of compounds
SG11201901126UA (en) Combination therapy for cancer
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201900361RA (en) Methods of treating prostate cancer
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201810443SA (en) Invasive medical devices including magnetic region and systems and methods
SG11201804699WA (en) Open-top microfluidic device with structural anchors
SG11201807487WA (en) Generation of midbrain-specific organoids from human pluripotent stem cells
SG11201804117XA (en) Neural cell extracellular vessicles
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201808125RA (en) Methods for solid tumor treatment